Abstract | BACKGROUND: METHODS AND RESULTS: One hundred nine of 122 eligible patients were randomized to four different groups: Group A (n = 28) received aprotinin starting with a bolus of 2 x 10(6) KIU followed by a continuous infusion of 0.5 x 10(6) KIU/h until the end of surgery; group B (n = 25) received of DDAVP 0.3 micrograms/kg i.v. on completion of CPB; group C (n = 28) received two doses of DDAVP, the first as in group B and an additional dose 6 hours after surgery; group D (n = 28) received no treatment. There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens. A significant reduction in the amount of blood used was observed only in the aprotinin group (P < .01). Of the plasma fibrinolytic components assayed, there was a significant reduction of the fibrin degradation product generation in the aprotinin group (P < .001), whereas a significant systemic hyperfibrinolysis was observed in both DDAVP-treated groups and the control group. No side effects related to the study drugs were observed in any patient. CONCLUSIONS:
|
Authors | E Rocha, F Hidalgo, R Llorens, J M Melero, J L Arroyo, J A Páramo |
Journal | Circulation
(Circulation)
Vol. 90
Issue 2
Pg. 921-7
(Aug 1994)
ISSN: 0009-7322 [Print] United States |
PMID | 7519132
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Aprotinin
- Deamino Arginine Vasopressin
|
Topics |
- Aprotinin
(therapeutic use)
- Blood Loss, Surgical
(prevention & control)
- Blood Transfusion
- Cardiopulmonary Bypass
- Deamino Arginine Vasopressin
(therapeutic use)
- Female
- Fibrinolysis
(drug effects)
- Hemorrhage
(prevention & control)
- Humans
- Male
- Middle Aged
- Postoperative Complications
(prevention & control)
- Prospective Studies
|